Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company is stepping back in second-line breast cancer.
